SCHEMBL2068765

SCHEMBL2068765

O=C(Nc1ccccc1)N(Cl)Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.56
TP53 P04637 1/20 0.56
EPHX1 P07099 1/20 0.56
TSHR P16473 1/20 0.56
EPHX2 P34913 1/20 0.56
CDK9 P50750 1/20 0.56
CLK4 Q9HAZ1 1/20 0.56
ALDH1A1 P00352 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55
HSD17B10 Q99714 2/20 0.55
MAPT P10636 2/20 0.55
RAB9A P51151 2/20 0.55
NPC1 O15118 1/20 0.55
ALOX15 P16050 1/20 0.55
NAPRT Q6XQN6 1/20 0.52
TGM2 P21980 1/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
MTOR P42345 2/20 0.50
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4359332 0.81 MEN1 (0.56) SMN1; SMN2TP53EPHX1TSHREPHX2
Fenuron SCHEMBL8366971 0.77 TSHR (0.64) TSHRHSD17B10NAPRTMEN1KMT2A
Fenuron SCHEMBL10806698 0.77 TSHR (0.64) TSHRHSD17B10NAPRTMEN1KMT2A
Fenuron SCHEMBL62004 0.77 TSHR (0.64) TSHRHSD17B10NAPRTMEN1KMT2A
Fenuron SCHEMBL9451054 0.77 TSHR (0.64) TSHRHSD17B10NAPRTMEN1KMT2A
SCHEMBL9518721 0.77 SMN1; SMN2 (0.56) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL6206532 0.77 SMN1; SMN2 (0.56) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL9142268 0.77 TGM2 (0.57) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL11229513 0.77 MTOR (0.54) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL1382899 0.76 MEN1 (0.67) SMN1; SMN2TP53EPHX1TSHREPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-9241544-A None JP disclosed
WO-2012103523-A3 NOVEL MODULATORS OF DEVELOPMENT OF ADIPOCYTE AND CANCER CELLS RAHBAR SAMUEL (US) 2012-09-20 WO disclosed
WO-2012103523-A2 NOVEL MODULATORS OF DEVELOPMENT OF ADIPOCYTE AND CANCER CELLS RAHBAR SAMUEL (US) 2012-08-02 WO disclosed
US-20110065958-A1 Low Temperature Curable Epoxy Compositions Containing Urea Curatives AIR PRODUCTS AND CHEMICALS, INC. (US) 2011-03-17 US disclosed
CN-1295075-A Metal organic compound and polymer therefrom ELF ATECHOM NORTH AMERICA INC (US) 2001-05-16 CN disclosed
EP-0991406-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2000-12-13 EP disclosed
EP-0991406-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-04-12 EP disclosed
WO-1998032439-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1998-07-30 WO disclosed
JP-H09241544-A MULTICOLOR-PATTERN COATING COMPOSITION WITH ANTIALGAL PROPERTIES KANSAI PAINT CO LTD 1997-09-16 JP disclosed
CN-1140176-A Metal organic compound and polymer made therefrom ATOCHEM NORTH AMERICA ELF (US) 1997-01-15 CN disclosed
EP-0535184-A1 NOVEL QUINOLONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME BOUCHARA S.A. (FR) 1993-04-07 EP disclosed
EP-0533895-A1 NOVEL QUINOLONES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BOUCHARA S.A. (FR) 1993-03-31 EP disclosed
WO-1992017466-A1 NOVEL QUINOLONES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BOUCHARA S.A. (FR) 1992-10-15 WO disclosed
WO-1992015574-A1 NOVEL QUINOLONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME BOUCHARA S.A. (FR) 1992-09-17 WO disclosed
US-4740540-A LOW-SMOKING DAINIPPON INK AND CHEMICALS, INC. (JP) 1988-04-26 US disclosed
EP-0166275-A2 Resin composition for molding material DAINIPPON INK AND CHEMICALS, INC. (JP) 1986-01-02 EP disclosed
EP-0044185-A2 Imidazolidinone derivatives ELI LILLY AND COMPANY (US) 1982-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065958-A1 Low Temperature Curable Epoxy Compositions Containing Urea Curatives H1-0, CARM1, KDM8 SMN1; SMN2 1927/4885TP53 1722/4885EPHX1 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.